AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. wa⦠read more
Healthcare
Biotechnology
- years
USD
Exclusive to Premium users
$0.79
Price-2.30%
-$0.02
$9.196m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-
5y CAGR-$1.636m
-
1y CAGR-
3y CAGR-
5y CAGR$5.43
-
1y CAGR-
3y CAGR-
5y CAGR-$15.852m
$11.662m
Assets$27.514m
Liabilities$16.436m
Debt140.9%
-0.9x
Debt to EBITDA-$13.580m
-
1y CAGR-
3y CAGR-
5y CAGR